SCHEMBL6096440

SCHEMBL6096440

O=C(O)C1(S(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)F)cc3)CC2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.49
MMP2 P08253 1/20 0.49
CHRM4 P08173 8/20 0.46
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
BACE1 P56817 2/20 0.46
CHRM2 P08172 2/20 0.46
LIPE Q05469 1/20 0.46
CHRM1 P11229 1/20 0.46
MMP14 P50281 2/20 0.45
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
HRH3 Q9Y5N1 2/20 0.44
MMP12 P39900 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095774 0.91 MMP1 (0.54) MMP13MMP2CHRM4BCHEACHE
SCHEMBL6097329 0.91 MMP13 (0.49) MMP13MMP2CHRM4BCHEACHE
SCHEMBL6096620 0.91 ADRB2 (0.52) MMP13MMP2LIPEHRH3MMP12
Hydrochloric Acid SCHEMBL6466769 0.90 MMP1 (0.53) MMP13MMP2CHRM4BCHEACHE
SCHEMBL6096556 0.84 MMP14 (0.54) MMP13MMP2MMP14MMP1MMP3
SCHEMBL6098455 0.82 MMP13 (0.49) MMP13MMP2LIPEMMP14MMP1
SCHEMBL6094760 0.82 MMP13 (0.49) MMP13MMP2LIPEMMP14MMP1
SCHEMBL6096414 0.82 MMP13 (0.49) MMP13MMP2LIPEMMP14MMP1
SCHEMBL6097858 0.82 ADRB2 (0.49) MMP13MMP2LIPEMMP1MMP9
SCHEMBL6096396 0.82 ADRB2 (0.54) MMP13MMP2MMP14MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed
EP-1157021-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
WO-2000046221-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 MMP13 23/4885MMP2 8/4885CHRM4 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.